Rosuvastatin belongs to a group of medicines called statins. They are prescribed to treat hyperlipidemia. Physiological levels of lipids in blood are an important aspect in prevention of cardiovascular diseases. Statins are HMG-CoA reductase inhibitors, liver enzyme taking part in cholesterol production. Rosuvastatin was patented in the nineties and approved for sale in the United States in 2003. Since 2016 rosuvastatin is available as a generic drug. Statins and especially rosuvastatin, are one of the most successful and profitable drugs worldwide. Structurally rosuvastatin is very similar to other synthetic statins with the exception of a sulfonamide functional group, present only in rosuvastatin.
The goal of this thesis was optimization of a method for determination of the impurity L in rosuvastatin calcium.
In the early stages we tried to optimize the method by using a variety of columns. Then we tried changing basic chromatographic conditions (mobile phase proportion, column temperature, flow). When also these changes did not yield satisfactory results, we opted for more radical modifications: solvent substitution, mobile phase composition, transition from UPLC (with binary pump) to UHPLC system (with quarternary pump).
When we obtained a suitable method with satisfactory resolution and sensitivity we performed its partial validation. We investigated basic validation parameters; limit of quantification, linearity, precision, accuracy, response factor and sample stability.
Validation confirmed that the new method is suitable for routine use.
|